A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma



The goal of this clinical trial is to find the best dose and learn more about the safety and effectiveness of maplirpacept (PF-07901801) in patients with advanced hematologic malignancies, including Lymphoma, Leukemia, and Multiple Myeloma.

SparkCures ID 1006
Trial Phase Phase 1
Enrollment 177 Patients
Trial Sponsors
  • Pfizer
NCT Identifier


Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Key Inclusion Criteria (Phase 1a and Phase 1b, all Cohorts):

  • Available fresh or archived tumor tissue.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.
  • Adequate coagulation function.
  • Adequate hepatic function.
  • Adequate hematologic status.
  • Adequate renal function.
  • Recovery from non-hematopoietic toxicities of previous anticancer drugs or radiotherapy or previous surgeries to ≤Grade 1 (or to baseline grade if condition was pre-existing).
  • Key Inclusion Criteria (Phase 1a): Histologically confirmed relapsed/refractory lymphoma (Hodgkin or non-Hodgkin).
  • Key Inclusion Criteria (Phase 1b Cohort A): Histologically confirmed, newly diagnosed TP53-mutated Acute Myeloid Leukemia (AML).
  • Key Inclusion Criteria (Phase 1b Cohort B): Histologically confirmed, newly diagnosed TP53-wildtype AML, elderly or unfit for more aggressive treatment.
  • Inclusion Criteria (Phase 1b Cohort C): Histologically documented relapsed/refractory Multiple Myeloma (MM).

Key Exclusion Criteria (Phase 1a and Phase 1b, all Cohorts):

  • Known, current central nervous system disease involvement.
  • Use of any investigational agent or any anticancer drug within 14 days before planned start of study treatment (within 4 weeks for antibody-based therapies and within 8 weeks for cell-based therapies).
  • Subjects who have undergone radiation therapy within 14 days of study treatment administration.
  • Hematopoietic stem cell transplant within 90 days before the planned start of study treatment or subjects with active graft-vs-host disease, with the exception of Grade 1 skin involvement.
  • Major surgery within 30 days before planned start of study treatment.

US Trial Locations

Please visit the ClinicalTrials.gov page for historical site information.

View Centers
SparkCures Verified

Learn more about how we work with trial sponsors